The Saudi Food and Drug Authority announced that the Kingdom has become the world’s first nation to grant conditional regulatory approval for Anktiva as a treatment for advanced non-small cell lung cancer, according to Gulf News.
The authority has granted conditional approval for Anktiva (nogapendekin alfa inbakicept), authorizing its use alongside immunotherapy in adults battling metastatic non-small cell lung cancer whose disease has seen progress despite prior treatment.
By granting this authorization, the authority stands as the world’s first regulatory body to grant approval for Anktiva in this indication.
In a parallel move, the authority also approved Anktiva with Bacillus Calmette-Guérin (BCG) for adults facing high‑risk, BCG‑unresponsive non‑muscle‑invasive bladder cancer with carcinoma in situ. Therefore, the decision offers new hope to patients with few remaining treatment options.
Anktiva represents a significant milestone with a breakthrough mechanism that targets the interleukin‑15 (IL‑15) receptor, rallying the body’s immune defenses by activating natural killer cells and vital T‑cell populations to fight cancer. Moreover, it helps avoid the growth of immune‑suppressive regulatory T cells.
The conditional approval for lung cancer was based on critical data from a single‑arm clinical study involving patients whose disease had advanced despite one or more prior treatments, including immune checkpoint inhibitors.
The trial noted a potential survival benefit, leading regulators to allow the drug’s use while mandating a confirmatory study to establish its long‑term benefit.
Related Topics:
KFSHRC Secures US Patent for Breast Cancer Treatment
MoH Sounds Alarm on Late-Stage Breast Cancer Diagnoses
Saudi Fund Establishes Cancer Hospital in Mauritius
